News & Media

Otsuka Pharmaceutical Development & Commercialization, Inc. and Sunovion Pharmaceuticals Inc. announced that the first patient has been enrolled in a Phase 2/3 clinical study to evaluate ulotaront (SEP-363856), a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT_1A agonist activity, as an adjunctive therapy in the treatment of adults living with major depressive disorder.

Otsuka America Pharmaceutical, Inc., and Lundbeck US presented positive efficacy and safety data from multiple Phase 3 studies of brexpiprazole in the treatment of agitation in patients with Alzheimer's dementia at the Clinical Trials for Alzheimer’s Disease (CTAD) Congress in San Francisco, CA.

Otsuka America Pharmaceutical, Inc. announces that it will integrate Avanir Pharmaceuticals into its business as of January 1, 2023. The move brings together the knowledge, capabilities and best practices of both companies to further advance solutions to treat central nervous system disorders. 

Otsuka and Lundbeck announce the U.S. Food and Drug Administration (FDA) acceptance of their New Drug Application (NDA) for aripiprazole 2-month, ready-to-use, long-acting injectable, a medication administered for the treatment of schizophrenia in adults and for maintenance monotherapy treatment of bipolar I disorder in adults.